Men's Health, Testosterone & Sexual Function • ICD-10-CM N52.32
Erectile dysfunction following radical cystectomy
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N52.32 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Erectile dysfunction following radical cystectomy Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry N52.32: Erectile dysfunction following radical cystectomy is managed within Men's Health & TRT.
- 3 Typical cash cost range: Clinicians assessing Erectile dysfunction following radical cystectomy focus on impaired cavernosal endothelial in Erectile dysfunction following radical cystectomy (N52.32: nitric oxide-cGMP smooth-muscle) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Erectile dysfunction following radical cystectomy: LH, FSH & in Erectile dysfunction following radical cystectomy (N52.32: SHBG) (LH/FSH 2.5 – 8.0 mIU/mL (N52.32)) and Hematocrit & Total in Erectile dysfunction following radical cystectomy (N52.32: PSA).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Erectile dysfunction following radical cystectomy
What Is Erectile dysfunction following radical cystectomy?
Recognized across U.S. clinical coding as N52.32 (Men's Health & TRT), Erectile dysfunction following radical cystectomy is evaluated via two fasting morning in Erectile dysfunction following radical cystectomy (N52.32: LC-MS/MS testosterone assays) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Erectile dysfunction following radical cystectomy (ICD-10 N52.32) is driven by impaired cavernosal endothelial in Erectile dysfunction following radical cystectomy (N52.32: nitric oxide-cGMP smooth-muscle); specialists in Men's Health, Testosterone & Sexual Function monitor Hematocrit & Total in Erectile dysfunction following radical cystectomy (N52.32: PSA) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Erectile dysfunction following radical cystectomy (N52.32): reduced sexual desire, in Erectile dysfunction following radical cystectomy (N52.32: fewer spontaneous morning)
- • Secondary Erectile dysfunction following radical cystectomy clinical sign: loss of lean in Erectile dysfunction following radical cystectomy (N52.32: muscle recovery, rising)
- • Symptom flares in Erectile dysfunction following radical cystectomy correlating with LH, FSH & in Erectile dysfunction following radical cystectomy (N52.32: SHBG) deviation outside LH/FSH 2.5 – 8.0 mIU/mL (N52.32)
- • Functional men's health & trt impact requiring two fasting morning in Erectile dysfunction following radical cystectomy (N52.32: LC-MS/MS testosterone assays) evaluation (N52.32)
Erectile dysfunction following radical cystectomy Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N52.32 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Men's Health, Testosterone & Sexual Function | NLM Clinical Tables |
| Diagnostic / Lab Marker: LH, FSH & in Erectile dysfunction following radical cystectomy (N52.32: SHBG) | LH/FSH 2.5 – 8.0 mIU/mL (N52.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hematocrit & Total in Erectile dysfunction following radical cystectomy (N52.32: PSA) | Hct < 50%; age-appropriate PSA (N52.32) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ultrasensitive Estradiol & in Erectile dysfunction following radical cystectomy (N52.32: ApoB) | E2 20–38 pg/mL; ApoB < 80 mg/dL (N52.32) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Erectile dysfunction following radical cystectomy
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Delafloxacin Meglumine Baxdela • RxCUI 1927667 | Fluoroquinolone Antibacterial | 93% | $1.0600 | $ 51.43 /mo |
| Iodixanol Visipaque • RxCUI RXN-65219381-1723 | Radiographic Contrast Agent | 87% | $3.2500 | $ 140.13 /mo |
| Cefazolin Cefazolin Generic • RxCUI 1665050 | Cephalosporin Antibacterial | 77% | $0.9744 | $ 47.96 /mo |
| Ultramicrosize Griseofulvin Ultramicrosize Griseofulvin Generic • RxCUI 239239 | Tubulin Inhibiting Agent | 79% | $2.6518 | $ 115.90 /mo |
| Cefaclor Ceclor • RxCUI 197449 | Cephalosporin Antibacterial | 86% | $0.8733 | $ 18.35 /mo |
| Cefepime Cefepime Generic • RxCUI 1665088 | Cephalosporin Antibacterial | 77% | $3.7308 | $ 159.60 /mo |
| Amphotericin B Amphotericin B Generic • RxCUI 967385 | Lipid-based Polyene Antifungal | 81% | $1.6500 | $ 75.33 /mo |
| Ioversol Optiray 320, Optiray • RxCUI RXN-00191323-1726 | Radiographic Contrast Agent | 83% | $2.8200 | $ 122.71 /mo |
| Diltiazem Hci Diltiazem Hci Generic • RxCUI 1791240 | Calcium Channel Blocker | 94% | $0.0935 | $ 12.29 /mo |
| Sporanox (Itraconazole) Sporanox • RxCUI 311204-B50458290 | Azole Antifungal | 90% | $27.6651 | $ 16.80 /mo |
| Sertraline Hydrochloride Sertraline HCl, Zoloft • RxCUI 312941 | Serotonin Reuptake Inhibitor | 89% | $0.0496 | $ 5.64 /mo |
| Quizartinib Vanflyta • RxCUI 2643054 | Kinase Inhibitor | 77% | $3.3600 | $ 144.58 /mo |
| Fludeoxyglucose F-18 Fludeoxyglucose F18 • RxCUI RXN-24450647-1722 | Radioactive Diagnostic Agent | 83% | $2.7500 | $ 119.88 /mo |
| Itraconazole Tolsura, Sporanox • RxCUI 311204 | Azole Antifungal | 89% | $0.7974 | $ 16.80 /mo |
| Oxiconazole Nitrate Oxistat • RxCUI 312139 | Azole Antifungal | 86% | $2.7247 | $ 93.93 /mo |
| Adenosine Tissen NF 10, Tissen Icm 10 • RxCUI 1654169 | Adenosine Receptor Agonist | 91% | $2.0100 | $ 89.91 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Erectile dysfunction following radical cystectomy)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of testosterone replacement therapy on lower urinary tract: What a 2,453-Participant Study Found The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Journal of evidence-based medicine • 2024-09-15 • Meta-Analysis | N = 2,453 | 99/100 | PMID 39004879 ↗ |
| New Insights on Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile: What a 1,458-Participant Study Found TTh achieved a significant improvement in the IIEF-EFD score of hypogonadal men compared with placebo, especially in those who received testosterone gel, were treated for over 30 weeks, and had no comorbidities. Urologia internationalis • 2022-01-15 • Meta-Analysis | N = 1,458 | 99/100 | PMID 34856556 ↗ |
| New Insights on Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating: What a 1,531-Participant Study Found Tadalafil combined with tamsulosin was more effective in the treatment of male LUTS/BPH, with or without ED, on the improvement of total IPSS, QoL, and Qmax. Urologia internationalis • 2024-01-15 • Meta-Analysis | N = 1,531 | 94/100 | PMID 38081154 ↗ |
| Combination Therapies vs. Single-drug treatment: Which Works Better for Erectile Dysfunction? A total of 44 studies included 3853 men with a mean (SD) age of 55.8 (11.9) years. JAMA network open • 2021-02-01 • Meta-Analysis | N = 3,853 | 94/100 | PMID 33599772 ↗ |
| New Insights on Benefits and safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to: What a 1,144-Participant Study Found However, therapy discontinuation due to pain and AEs did not increase with increase in AEs. American journal of men's health • 2020-01-15 • Meta-Analysis | N = 1,144 | 94/100 | PMID 33342335 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Erectile dysfunction following radical cystectomy Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Erectile dysfunction following radical cystectomy community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Erectile dysfunction following radical cystectomy.
Related Conditions in Men's Health, Testosterone & Sexual Function
Male Hypogonadism & Androgen Deficiency
ICD-10 E29.1
Vasculogenic Erectile Dysfunction & Lower Urinary Tract BPH
ICD-10 N52.9
Erectile Dysfunction
ICD-10 N52.9
Hormones
ICD-10 E29.1
Safety
ICD-10 E29.6
Sexual Problems in Men
ICD-10 N52.5
Hypogonadism - male
ICD-10 E29.1
Testicular hyperfunction
ICD-10 E29.0